PMID: 26838239Feb 4, 2016Paper

Acute Myeloid Leukemia: Clinical Spectrum of 125 Patients

Asian Pacific Journal of Cancer Prevention : APJCP
Sadia SultanSana Ashar

Abstract

Acute myeloid leukemia is an acquired clonal heterogeneous stem cell disorder. Hence, various parameters are sought out to categorize this disease into subtypes, so that as a consequence specific treatment modalities can be offered. Conventionally, the practically used method for classification utilizes French American British (FAB) criteria based on morphology and cytochemistry. The aim of present study was to determine the current spectrum of AML sub types in patients in Karachi. This single centre cross sectional study was conducted at Liaquat National Hospital, Karachi, extending from January 2010 to December 2014. Data were retrieved from archives were analyzed with SPSS version 22. A total of 125 patients were diagnosed at our institution with de novo AML during five years period, 76 males and 49 females. Median age was 34.5 years. AML-M1 was the predominant FAB subtype (23.2%) followed by M2 (18.4%), M3 and M4 (16% each), M0 (14.4%), M5 (7.2%), M6 (3.2%) and M7 (1.6%). AML in Pakistani patients is seen in a relatively young population. The most common FAB subtype observed in our study was acute myeloblastic leukemia, without maturation (M1).

References

Aug 7, 2002·Current Oncology Reports·Claudia Schoch, Torsten Haferlach
Mar 8, 2007·Annals of Saudi Medicine·M S HarakatiK S Al-Khairy
Jun 6, 2009·Journal of Hematology & Oncology·Tara K GregoryWilliam Tse
Jan 16, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Xiao-Fei YangDe-Pei Wu
Jul 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Lei ZhouZhuo-Gang Liu
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Long SuYing-Min Liu
Nov 25, 2014·Haematologica·Richard F Schlenk
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.